MDM2 acts as a major regulator of the tumor suppressor p53 (MIM.191170) by targeting its destruction. p14ARF increases p53 levels by inhibiting MDM2 activity.

Pathology

 MDM2 amplification and overexpression in tumors

• leukemias (#8219216#)
• liposarcomas (#16160477#)
  • atypical lipomatous tumor/well-differentiated liposarcoma (ALT-WDLPS) (#16160477#)
  • dedifferentiated liposarcoma (DDLPS) (#16160477#)

References

 Binh MB, Sastre-Garau X, Guillou L, Pinieux GD, Terrier P, Lagace R, Aurias A, Hostein I, Coindre JM. MDM2 and CDK4 Immunostainings Are Useful Adjuncts in Diagnosing Well-Differentiated and Dedifferentiated Liposarcoma Subtypes: A Comparative Analysis of 559 Soft Tissue Neoplasms With Genetic Data. Am J Surg Pathol. 2005 Oct;29(10):1340-1347. PMID: #16160477#

 Harris LC. MDM2 splice variants and their therapeutic implications. Curr Cancer Drug Targets. 2005 Feb;5(1):21-6. PMID: #15720186#

 Chene P. Inhibiting the p53-MDM2 interaction: an important target for cancer therapy. Nat Rev Cancer. 2003 Feb;3(2):102-9. PMID: #12563309#

 Daujat S, Neel H, Piette J. MDM2: life without p53. Trends Genet. 2001 Aug;17(8):459-64. PMID: #11485818#